Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer

Ernest K Amankwah; Linda E Kelemen; Qinggang Wang; Honglin Song; Georgia Chenevix-Trench; Jonathan Beesley; Penelope M Webb; Celeste L Pearce; Anna H Wu; Malcolm C Pike; Daniel O Stram; Jenny Chang-Claude; Shan Wang-Gohrke; Roberta B Ness; Ellen L Goode; Julie M Cunningham; Brooke L Fridley; Robert A Vierkant; Shelley S Tworoger; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; Susan J Ramus; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Michael E Carney; Galina Lurie; Lynne R Wilkens; Susanne Krüger Kjær; Estrid Høgdall; Daniel W Cramer; Kathryn L Terry; Montserrat Garcia-Closas; Hannah Yang; Jolanta Lissowska; Hoda Anton-Culver; Argyrios Ziogas; Joellen M Schildkraut; Andrew Berchuck; Paul D P Pharoah; on behalf of the Australian Ovarian Cancer Study Group

doi:http://dx.doi.org/10.1158/1055-9965.EPI-11-0053

Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer

Ernest K Amankwah, Linda E Kelemen, Qinggang Wang, Honglin Song, Georgia Chenevix-Trench, Jonathan Beesley, Penelope M Webb, Celeste L Pearce, Anna H Wu, Malcolm C Pike, Daniel O Stram, Jenny Chang-Claude, Shan Wang-Gohrke, Roberta B Ness, Ellen L Goode, Julie M Cunningham, Brooke L Fridley, Robert A Vierkant, Shelley S Tworoger, Alice S WhittemoreValerie McGuire, Weiva Sieh, Simon A Gayther, Aleksandra Gentry-Maharaj, Usha Menon, Susan J Ramus, Mary Anne Rossing, Jennifer A Doherty, Marc T Goodman, Michael E Carney, Galina Lurie, Lynne R Wilkens, Susanne Krüger Kjær, Estrid Høgdall, Daniel W Cramer, Kathryn L Terry, Montserrat Garcia-Closas, Hannah Yang, Jolanta Lissowska, Hoda Anton-Culver, Argyrios Ziogas, Joellen M Schildkraut, Andrew Berchuck, Paul D P Pharoah, on behalf of the Australian Ovarian Cancer Study Group

Abstract

Background: We previously reported an association between rs2660753, a prostate cancer susceptibility polymorphism, and invasive epithelial ovarian cancer (EOC; OR = 1.2, 95% CI= 1.0-1.4, P_trend = 0.01) that showed a stronger association with the serous histological subtype (OR = 1.3, 95% CI = 1.1-1.5, P_trend = 0.003). Methods: We sought to replicate this association in 12 other studies comprising 4,482 cases and 6,894 controls of white non-Hispanic ancestry in the Ovarian Cancer Association Consortium. Results: No evidence for an association with all cancers or serous cancers was observed in a combined analysis of data from the replication studies (all: OR = 1.0, 95% CI = 0.9-1.1, P_trend = 0.61; serous: OR = 1.0, 95% CI = 0.9-1.1, P_trend = 0.85) or from the combined analysis of discovery and replication studies (all: OR = 1.0, 95% CI = 1.0-1.1, P_trend = 0.28; serous: OR = 1.1, 95% CI = 1.0-1.2, P_trend = 0.11). There was no evidence for statistical heterogeneity in ORs across the studies. Conclusions: Although rs2660753 is a strong prostate cancer susceptibility polymorphism, the association with another hormonally related cancer, invasive EOC, is not supported by this replication study. Impact: Our findings, based on a larger sample size, emphasize the importance of replicating potentially promising genetic risk associations.

Original language	English
Journal	Cancer Epidemiology, Biomarkers & Prevention
Volume	20
Issue number	5
Pages (from-to)	1028-1031
Number of pages	4
ISSN	1055-9965
DOIs	https://doi.org/10.1158/1055-9965.EPI-11-0053
Publication status	Published - 1 May 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://dx.doi.org/10.1158/1055-9965.EPI-11-0053

Cite this

Amankwah, E. K., Kelemen, L. E., Wang, Q., Song, H., Chenevix-Trench, G., Beesley, J., Webb, P. M., Pearce, C. L., Wu, A. H., Pike, M. C., Stram, D. O., Chang-Claude, J., Wang-Gohrke, S., Ness, R. B., Goode, E. L., Cunningham, J. M., Fridley, B. L., Vierkant, R. A., Tworoger, S. S., ... on behalf of the Australian Ovarian Cancer Study Group (2011). Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer. Cancer Epidemiology, Biomarkers & Prevention, 20(5), 1028-1031. https://doi.org/10.1158/1055-9965.EPI-11-0053

Amankwah, EK, Kelemen, LE, Wang, Q, Song, H, Chenevix-Trench, G, Beesley, J, Webb, PM, Pearce, CL, Wu, AH, Pike, MC, Stram, DO, Chang-Claude, J, Wang-Gohrke, S, Ness, RB, Goode, EL, Cunningham, JM, Fridley, BL, Vierkant, RA, Tworoger, SS, Whittemore, AS, McGuire, V, Sieh, W, Gayther, SA, Gentry-Maharaj, A, Menon, U, Ramus, SJ, Rossing, MA, Doherty, JA, Goodman, MT, Carney, ME, Lurie, G, Wilkens, LR, Kjær, SK, Høgdall, E, Cramer, DW, Terry, KL, Garcia-Closas, M, Yang, H, Lissowska, J, Anton-Culver, H, Ziogas, A, Schildkraut, JM, Berchuck, A, Pharoah, PDP & on behalf of the Australian Ovarian Cancer Study Group 2011, 'Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer', Cancer Epidemiology, Biomarkers & Prevention, vol. 20, no. 5, pp. 1028-1031. https://doi.org/10.1158/1055-9965.EPI-11-0053

@article{f02b369b51404bbeb6c747764fccfe00,

title = "Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer",

abstract = "Background: We previously reported an association between rs2660753, a prostate cancer susceptibility polymorphism, and invasive epithelial ovarian cancer (EOC; OR = 1.2, 95% CI= 1.0-1.4, Ptrend = 0.01) that showed a stronger association with the serous histological subtype (OR = 1.3, 95% CI = 1.1-1.5, Ptrend = 0.003). Methods: We sought to replicate this association in 12 other studies comprising 4,482 cases and 6,894 controls of white non-Hispanic ancestry in the Ovarian Cancer Association Consortium. Results: No evidence for an association with all cancers or serous cancers was observed in a combined analysis of data from the replication studies (all: OR = 1.0, 95% CI = 0.9-1.1, Ptrend = 0.61; serous: OR = 1.0, 95% CI = 0.9-1.1, Ptrend = 0.85) or from the combined analysis of discovery and replication studies (all: OR = 1.0, 95% CI = 1.0-1.1, Ptrend = 0.28; serous: OR = 1.1, 95% CI = 1.0-1.2, Ptrend = 0.11). There was no evidence for statistical heterogeneity in ORs across the studies. Conclusions: Although rs2660753 is a strong prostate cancer susceptibility polymorphism, the association with another hormonally related cancer, invasive EOC, is not supported by this replication study. Impact: Our findings, based on a larger sample size, emphasize the importance of replicating potentially promising genetic risk associations.",

author = "Amankwah, {Ernest K} and Kelemen, {Linda E} and Qinggang Wang and Honglin Song and Georgia Chenevix-Trench and Jonathan Beesley and Webb, {Penelope M} and Pearce, {Celeste L} and Wu, {Anna H} and Pike, {Malcolm C} and Stram, {Daniel O} and Jenny Chang-Claude and Shan Wang-Gohrke and Ness, {Roberta B} and Goode, {Ellen L} and Cunningham, {Julie M} and Fridley, {Brooke L} and Vierkant, {Robert A} and Tworoger, {Shelley S} and Whittemore, {Alice S} and Valerie McGuire and Weiva Sieh and Gayther, {Simon A} and Aleksandra Gentry-Maharaj and Usha Menon and Ramus, {Susan J} and Rossing, {Mary Anne} and Doherty, {Jennifer A} and Goodman, {Marc T} and Carney, {Michael E} and Galina Lurie and Wilkens, {Lynne R} and Kj{\ae}r, {Susanne Kr{\"u}ger} and Estrid H{\o}gdall and Cramer, {Daniel W} and Terry, {Kathryn L} and Montserrat Garcia-Closas and Hannah Yang and Jolanta Lissowska and Hoda Anton-Culver and Argyrios Ziogas and Schildkraut, {Joellen M} and Andrew Berchuck and Pharoah, {Paul D P} and H{\o}gdall, {Estrid Vilma Solyom}",

year = "2011",

month = may,

day = "1",

doi = "http://dx.doi.org/10.1158/1055-9965.EPI-11-0053",

language = "English",

volume = "20",

pages = "1028--1031",

journal = "Cancer Epidemiology, Biomarkers & Prevention",

issn = "1055-9965",

publisher = "American Association for Cancer Research (A A C R)",

number = "5",

}

TY - JOUR

T1 - Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer

AU - Amankwah, Ernest K

AU - Kelemen, Linda E

AU - Wang, Qinggang

AU - Song, Honglin

AU - Chenevix-Trench, Georgia

AU - Beesley, Jonathan

AU - Webb, Penelope M

AU - Pearce, Celeste L

AU - Wu, Anna H

AU - Pike, Malcolm C

AU - Stram, Daniel O

AU - Chang-Claude, Jenny

AU - Wang-Gohrke, Shan

AU - Ness, Roberta B

AU - Goode, Ellen L

AU - Cunningham, Julie M

AU - Fridley, Brooke L

AU - Vierkant, Robert A

AU - Tworoger, Shelley S

AU - Whittemore, Alice S

AU - McGuire, Valerie

AU - Sieh, Weiva

AU - Gayther, Simon A

AU - Gentry-Maharaj, Aleksandra

AU - Menon, Usha

AU - Ramus, Susan J

AU - Rossing, Mary Anne

AU - Doherty, Jennifer A

AU - Goodman, Marc T

AU - Carney, Michael E

AU - Lurie, Galina

AU - Wilkens, Lynne R

AU - Kjær, Susanne Krüger

AU - Høgdall, Estrid

AU - Cramer, Daniel W

AU - Terry, Kathryn L

AU - Garcia-Closas, Montserrat

AU - Yang, Hannah

AU - Lissowska, Jolanta

AU - Anton-Culver, Hoda

AU - Ziogas, Argyrios

AU - Schildkraut, Joellen M

AU - Berchuck, Andrew

AU - Pharoah, Paul D P

AU - on behalf of the Australian Ovarian Cancer Study Group

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Background: We previously reported an association between rs2660753, a prostate cancer susceptibility polymorphism, and invasive epithelial ovarian cancer (EOC; OR = 1.2, 95% CI= 1.0-1.4, Ptrend = 0.01) that showed a stronger association with the serous histological subtype (OR = 1.3, 95% CI = 1.1-1.5, Ptrend = 0.003). Methods: We sought to replicate this association in 12 other studies comprising 4,482 cases and 6,894 controls of white non-Hispanic ancestry in the Ovarian Cancer Association Consortium. Results: No evidence for an association with all cancers or serous cancers was observed in a combined analysis of data from the replication studies (all: OR = 1.0, 95% CI = 0.9-1.1, Ptrend = 0.61; serous: OR = 1.0, 95% CI = 0.9-1.1, Ptrend = 0.85) or from the combined analysis of discovery and replication studies (all: OR = 1.0, 95% CI = 1.0-1.1, Ptrend = 0.28; serous: OR = 1.1, 95% CI = 1.0-1.2, Ptrend = 0.11). There was no evidence for statistical heterogeneity in ORs across the studies. Conclusions: Although rs2660753 is a strong prostate cancer susceptibility polymorphism, the association with another hormonally related cancer, invasive EOC, is not supported by this replication study. Impact: Our findings, based on a larger sample size, emphasize the importance of replicating potentially promising genetic risk associations.

AB - Background: We previously reported an association between rs2660753, a prostate cancer susceptibility polymorphism, and invasive epithelial ovarian cancer (EOC; OR = 1.2, 95% CI= 1.0-1.4, Ptrend = 0.01) that showed a stronger association with the serous histological subtype (OR = 1.3, 95% CI = 1.1-1.5, Ptrend = 0.003). Methods: We sought to replicate this association in 12 other studies comprising 4,482 cases and 6,894 controls of white non-Hispanic ancestry in the Ovarian Cancer Association Consortium. Results: No evidence for an association with all cancers or serous cancers was observed in a combined analysis of data from the replication studies (all: OR = 1.0, 95% CI = 0.9-1.1, Ptrend = 0.61; serous: OR = 1.0, 95% CI = 0.9-1.1, Ptrend = 0.85) or from the combined analysis of discovery and replication studies (all: OR = 1.0, 95% CI = 1.0-1.1, Ptrend = 0.28; serous: OR = 1.1, 95% CI = 1.0-1.2, Ptrend = 0.11). There was no evidence for statistical heterogeneity in ORs across the studies. Conclusions: Although rs2660753 is a strong prostate cancer susceptibility polymorphism, the association with another hormonally related cancer, invasive EOC, is not supported by this replication study. Impact: Our findings, based on a larger sample size, emphasize the importance of replicating potentially promising genetic risk associations.

U2 - http://dx.doi.org/10.1158/1055-9965.EPI-11-0053

DO - http://dx.doi.org/10.1158/1055-9965.EPI-11-0053

M3 - Journal article

SN - 1055-9965

VL - 20

SP - 1028

EP - 1031

JO - Cancer Epidemiology, Biomarkers & Prevention

JF - Cancer Epidemiology, Biomarkers & Prevention

IS - 5

ER -

Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this